tetano
Editor, Senior Moderator
BMC Public Health
. 2024 Apr 26;24(1):1171.
doi: 10.1186/s12889-024-18576-w. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022)
Lander Willem[SUP] 1 2 [/SUP], Steven Abrams[SUP] 3 4 [/SUP], Nicolas Franco[SUP] 4 5 [/SUP], Pietro Coletti[SUP] 4 [/SUP], Pieter J K Libin[SUP] 4 6 7 [/SUP], James Wambua[SUP] 4 [/SUP], Simon Couvreur[SUP] 8 [/SUP], Emmanuel André[SUP] 9 10 [/SUP], Tom Wenseleers[SUP] 11 [/SUP], Zhuxin Mao[SUP] 12 [/SUP], Andrea Torneri[SUP] 4 [/SUP], Christel Faes[SUP] 4 [/SUP], Philippe Beutels[SUP] 12 13 [/SUP], Niel Hens[SUP] 12 4 [/SUP]
Affiliations
Background: When formulating and evaluating COVID-19 vaccination strategies, an emphasis has been placed on preventing severe disease that overburdens healthcare systems and leads to mortality. However, more conventional outcomes such as quality-adjusted life years (QALYs) and inequality indicators are warranted as additional information for policymakers.
Methods: We adopted a mathematical transmission model to describe the infectious disease dynamics of SARS-COV-2, including disease mortality and morbidity, and to evaluate (non)pharmaceutical interventions. Therefore, we considered temporal immunity levels, together with the distinct transmissibility of variants of concern (VOCs) and their corresponding vaccine effectiveness. We included both general and age-specific characteristics related to SARS-CoV-2 vaccination. Our scenario study is informed by data from Belgium, focusing on the period from August 2021 until February 2022, when vaccination for children aged 5-11 years was initially not yet licensed and first booster doses were administered to adults. More specifically, we investigated the potential impact of an earlier vaccination programme for children and increased or reduced historical adult booster dose uptake.
Results: Through simulations, we demonstrate that increasing vaccine uptake in children aged 5-11 years in August-September 2021 could have led to reduced disease incidence and ICU occupancy, which was an essential indicator for implementing non-pharmaceutical interventions and maintaining healthcare system functionality. However, an enhanced booster dose regimen for adults from November 2021 onward could have resulted in more substantial cumulative QALY gains, particularly through the prevention of elevated levels of infection and disease incidence associated with the emergence of Omicron VOC. In both scenarios, the need for non-pharmaceutical interventions could have decreased, potentially boosting economic activity and mental well-being.
Conclusions: When calculating the impact of measures to mitigate disease spread in terms of life years lost due to COVID-19 mortality, we highlight the impact of COVID-19 on the health-related quality of life of survivors. Our study underscores that disease-related morbidity could constitute a significant part of the overall health burden. Our quantitative findings depend on the specific setup of the interventions under review, which is open to debate or should be contextualised within future situations.
Keywords: COVID-19; Model; Non-pharmaceutical intervention; QALY; SARS-CoV-2; Vaccine.
. 2024 Apr 26;24(1):1171.
doi: 10.1186/s12889-024-18576-w. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022)
Lander Willem[SUP] 1 2 [/SUP], Steven Abrams[SUP] 3 4 [/SUP], Nicolas Franco[SUP] 4 5 [/SUP], Pietro Coletti[SUP] 4 [/SUP], Pieter J K Libin[SUP] 4 6 7 [/SUP], James Wambua[SUP] 4 [/SUP], Simon Couvreur[SUP] 8 [/SUP], Emmanuel André[SUP] 9 10 [/SUP], Tom Wenseleers[SUP] 11 [/SUP], Zhuxin Mao[SUP] 12 [/SUP], Andrea Torneri[SUP] 4 [/SUP], Christel Faes[SUP] 4 [/SUP], Philippe Beutels[SUP] 12 13 [/SUP], Niel Hens[SUP] 12 4 [/SUP]
Affiliations
- PMID: 38671366
- PMCID: PMC11047051
- DOI: 10.1186/s12889-024-18576-w
Background: When formulating and evaluating COVID-19 vaccination strategies, an emphasis has been placed on preventing severe disease that overburdens healthcare systems and leads to mortality. However, more conventional outcomes such as quality-adjusted life years (QALYs) and inequality indicators are warranted as additional information for policymakers.
Methods: We adopted a mathematical transmission model to describe the infectious disease dynamics of SARS-COV-2, including disease mortality and morbidity, and to evaluate (non)pharmaceutical interventions. Therefore, we considered temporal immunity levels, together with the distinct transmissibility of variants of concern (VOCs) and their corresponding vaccine effectiveness. We included both general and age-specific characteristics related to SARS-CoV-2 vaccination. Our scenario study is informed by data from Belgium, focusing on the period from August 2021 until February 2022, when vaccination for children aged 5-11 years was initially not yet licensed and first booster doses were administered to adults. More specifically, we investigated the potential impact of an earlier vaccination programme for children and increased or reduced historical adult booster dose uptake.
Results: Through simulations, we demonstrate that increasing vaccine uptake in children aged 5-11 years in August-September 2021 could have led to reduced disease incidence and ICU occupancy, which was an essential indicator for implementing non-pharmaceutical interventions and maintaining healthcare system functionality. However, an enhanced booster dose regimen for adults from November 2021 onward could have resulted in more substantial cumulative QALY gains, particularly through the prevention of elevated levels of infection and disease incidence associated with the emergence of Omicron VOC. In both scenarios, the need for non-pharmaceutical interventions could have decreased, potentially boosting economic activity and mental well-being.
Conclusions: When calculating the impact of measures to mitigate disease spread in terms of life years lost due to COVID-19 mortality, we highlight the impact of COVID-19 on the health-related quality of life of survivors. Our study underscores that disease-related morbidity could constitute a significant part of the overall health burden. Our quantitative findings depend on the specific setup of the interventions under review, which is open to debate or should be contextualised within future situations.
Keywords: COVID-19; Model; Non-pharmaceutical intervention; QALY; SARS-CoV-2; Vaccine.